Quarterly Result25 May 2026, 09:11 pm
Aarti Pharmalabs: FY26 Revenue at ₹1797.55 Mn, Dividend ₹2/Share
AI Summary
Aarti Pharmalabs Ltd's board approved the audited financial results for the year ended March 31, 2026. The company reported revenue from operations (net) of ₹1797.55 million for FY26. The board recommended a final dividend of ₹2 per equity share of face value ₹5 each, subject to shareholder approval. Smt. Ketki D. Visariya was re-appointed as Cost Auditor and Manish Modi & Associates as Internal Auditor for FY 2026-27. Mr. Sachin Patil and Mr. Rajendra Pagare were designated as Senior Management Personnel.
Key Highlights
- Aarti Pharmalabs FY26 revenue from operations (net) is ₹1797.55 million.
- Final dividend of ₹2 per share recommended for FY26.
- Ketki D. Visariya re-appointed as Cost Auditor for FY27.
- Manish Modi & Associates re-appointed as Internal Auditor for FY27.
- Sachin Patil and Rajendra Pagare designated as Senior Management Personnel.
Price Impact
More from AARTIPHARM